Manidipine dihydrochloride

Research use only, not for human use.

A dihydropyridine type calcium channel blocker that is used as an antihypertensive.

A dihydropyridine type calcium channel blocker that is used as an antihypertensive.Hypertension Approved.

——

Animal Model:IFNAR-/- miceDosage:10 mg/kg Administration:Intraperitoneal injection (i.p. ), b.i.d. at day 4, day 5 Result:Exhibited a modest, but statistically significant increase in the survival rate of lethal animal model with SFTSV infection, significantly reduced viral titers in the spleen and kidney.Animal Model:Adult female BALB/c mice (age, 4 weeks) Dosage:25 mg/kg Administration:Intraperitoneal injection (i.p. ), b.i.d. for 2 days, then daily for 19 days Result:Reduced the mortality rate from 73% to 20%, significantly reduced the viral load in infected mice while remarkably alleviated brain damage phenomena. Had little effect on peripheral JEV infection, which indicated that manidipine protected the mice against JEV-induced lethality by decreasing the viral load in the brain.Animal Model:8-week-old male Wistar rats Dosage:3 mg/kg Administration:Intragastric gavage (i.g.), once per day for 7 d Result:Prevented isoproterenol-induced left ventricular hypertrophy (2.26±0.02 g/kg;p<0.01) as isoproterenol increased left ventricular weight (2.40±0.04 g/kg; p<0.01). Inhibited expression of mRNA of ANP (0.9-fold of the control value; p<0.01), collagen types I (1.1-fold; p<0.01) and type III (1.6-fold; p<0.01), and fibronectin (1.1-fold; p<0.01).

CV-4093

GPCR/G Protein

Calcium Channel

CalciumChannel

Cardiovascular Disease

Hypertension

89226-75-5

683.6213

C35H40Cl2N4O6

>98% (HPLC)

10 mM in DMSO

[H+].[H+].[Cl-].[Cl-].COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1

3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 3-[2-[4-(diphenylmethyl)-1-piperazinyl]ethyl] 5-methyl ester, hydrochloride (1:2)

(-20℃)

With Ice Pack

≥ 2 years